Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference
May 30 2023 - 9:00AM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, today announced its participation in
the William Blair 43rd Annual Growth Stock Conference, which takes
place June 6-8, 2023, in Chicago at the Loews Chicago Hotel. John
Aballi, Exagen’s President and Chief Executive Officer, and Kamal
Adawi, Exagen’s Chief Financial Officer, will present on Wednesday,
June 7th, at 2:00 PM CT. Interested parties may access the webcast
of the presentation using a link on Exagen’s website at
https://investors.exagen.com/events.
About Exagen Inc.
Exagen is a leading provider of autoimmune diagnostic,
prognostic, and monitoring testing solutions. Exagen is a
patient focused, discovery driven organization built on the success
of AVISE® testing and is investing in its product pipeline to
support patients throughout their autoimmune diagnosis and
treatment journeys. The goal at Exagen is to assist patients,
physicians, and payors by enabling precision
medicine. Exagen is located in San Diego County.
For more information, please visit Exagen.com and
follow @ExagenInc on Twitter.
Forward Looking Statements
Exagen cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on Exagen's
current beliefs and expectations. The inclusion of forward-looking
statements should not be regarded as a representation by Exagen
that any of its plans will be achieved. Actual results may differ
from those set forth in this press release due to the risks and
uncertainties inherent in Exagen’s business, including, without
limitation: the COVID-19 pandemic may continue to adversely affect
its business, financial condition and results of operations,
including as a result of slowdown in its operations as well as
those of its suppliers and courier services, impeding patient
movement and interruptions to healthcare services causing a
decrease in test volumes, disruptions to the supply chain of
material needed for its tests causing an increase in cost per test,
its sales and commercialization activities and its ability to
receive specimens and perform or deliver the results from its
tests, delays in reimbursement and coverage decisions from Medicare
and third-party payors and in interactions with regulatory
authorities, and delays in ongoing and planned clinical trials
involving its tests; Exagen’s commercial success depends upon
attaining and maintaining significant market acceptance of its
testing products among rheumatologists, patients, third-party
payors and others in the medical community; Exagen’s ability to
successfully execute on its business strategies; third party payors
not providing coverage and adequate reimbursement for Exagen’s
testing products, including Exagen’s ability to collect on funds
due; Exagen’s ability to obtain and maintain intellectual property
protection for its testing products; regulatory developments
affecting Exagen’s business; and other risks described in Exagen’s
prior press releases and Exagen’s filings with the Securities and
Exchange Commission (“SEC”), including under the heading “Risk
Factors” in Exagen’s Annual Report on Form 10-K for the year ended
December 31, 2022 and any subsequent filings with the SEC. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and Exagen
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date
hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, which is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
Investor RelationsExagen Inc. Ryan
Douglasrdouglas@exagen.com 760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jul 2023 to Jul 2024